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Abstract
Background: Identifying the drug-deliverables that target autophagy is crucial to finding a cure for pancreatic cancer
(PC), as activated autophagy is associated with poor patient outcomes. Our recent studies recognized the anti-PC
potential of an antioxidant-rich collection of seaweed polyphenols and identified potential compounds for the
treatment of PC. Accordingly, we investigated whether such compounds could regulate autophagy in therapy-resistant
PC cells in vitro and in residual PC in vivo.
Results: Human Panc-3.27 and MiaPaCa-2 cells were exposed to fractionated irradiation (FIR) with/without ethyl acetate
(EA) polyphenol from Spatoglossum asperum (SA-EA), Padina tetrastromatica (PT-EA), or Hormophysa triquerta (HT-EA).
The cells were subjected to QPCR to examine transcriptional alterations in the following autophagy functional
regulators: ATG3, ATG5, ATG7, ATG12, LC3A, LC3B, Beclin, Myd88, HMGB1, Rage, and TLRs 1-9. Using a clinically relevant
mouse model of residual PC, we use tissue microarray (TMA) and immunohistochemistry (IHC) procedures to
investigate the potential of polyphenol(s) to target ATG3, ATG5, ATG12, LC3A, LC3B, BECN1, and SURIVIN after clinical
radiotherapy. Radiation significantly increased the transcription of autophagy functional regulators in both cell lines.
Seaweed polyphenols completely suppressed the transcription of all investigated autophagy regulators in both
cell-lines. Gene silencing approach defined the role of LC3B in radiation-induced cell survival in this setting. TMA-IHC
analysis revealed the complete regulation of ATG3, ATG5, ATG12, LC3A, LC3B, BECN1, and SURVIVIN in residual PC
following SA-EA, PT-EA, and HT-EA treatment.
Conclusions: These data demonstrate the autophagy blue print in therapy-resistant PC cells for the first time.
Moreover, the data strongly suggest that the selected polyphenols could serve as effective adjuvants for current
PC treatment modalities and may inhibit tumor relapse by comprehensively targeting therapy-orchestrated autophagy
in residual cells.
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Background
Autophagy is the sequential process by which the cyto-
plasmic components are engulfed by phagophore, isolated
in autophagosome, and broken down in the lysosome [1].
Autophagy, a well-regulated cell survival mechanism, plays
a crucial role in the maintenance of normal human
physiological processes, including cellular homeostasis,
energetic balance, and development [2,3]. Conversely, au-
tophagy is also implicated in the pathogenesis of many
diseases, including cancer [4-8]. Autophagy, through its
ability to shape inflammatory reactions [9], metabolic re-
quirements [10], and oxidative stress [11], plays a multi-
faceted role in cancer [8,12-15], including increasing
tumorigenesis and enhancing cancer development [16,17].
Compared with other epithelial cancers, pancreatic cancer
(PC) generally exhibits high basal autophagy [18]. Acti-
vated autophagy is correlated with poor patient outcomes
[19]. Primary therapeutic modalities for PC have been
shown to galvanize autophagy [20-23]. Additional studies
have recognized its cytoprotective role following chemo-
radiotherapy [24,25]. Reactive oxygen species (ROS) tox-
icity, the mechanism upon which radiotherapy and some
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chemotherapy agents rely to eradicate tumor cells, has
also been shown to regulate intracellular processes, in-
cluding apoptosis and autophagy [26]. In this study, we in-
vestigated the autophagy-related molecular programming
in human PC cells that survive first-line therapy.
The molecular orchestration of autophagy is complex
and involves more than 30 autophagy-related genes
(ATGs) [27,28]. Silencing these crucial autophagy drivers
significantly inhibits cell growth and colony formation of
PC cells [16]. Moreover, studies have shown that inhib-
ition of autophagy augments the production of ROS, in-
creased DNA damage, and regulates metabolism [16],
suggesting the key role of autophagy in PC via the regu-
lation of mitochondrial function and energy production.
Identifying autophagy inhibitors that could be used in
combination with chemotherapy, radiotherapy, and/or
immunotherapy [29] may provide clinical benefits in the
treatment of PC [18,16]. Recognizing a drug-deliverable
that not only regulates basal elevated levels of autophagy,
but also targets the therapy-associated onset, activation,
and maintenance of autophagy would have momentous
impact in the mitigation of PC relapse and metastasis, the
major hurdles to curing PC. To our knowledge, no studies
have attempted to examine potential of seaweeds or sea-
weed fractions (polyphenols) to inhibit autophagy in PC
or other tumor models. This study investigates the
autophagy-inhibiting potential of anti-oxidant rich sea-
weed polyphenol fractions.
The cells that survive first-line therapy exert immense
adaptive resistance to the successive courses of therapy
and further play crucial roles in the relapse, recurrence,
and dissemination of disease to distant organs. As dis-
cussed above, the onset of autophagy-associated survival
signaling has been demonstrated after primary therapeutic
treatment, at least in PC. Identifying the adjuvants that
mitigate the activation of autophagy-associated survival
signaling in therapy-resistant cells could help us to cure
PC. In the recent past, a number of epidemiological and
experimental studies have attempted to identify the bene-
fits of dietary habits, including the consumption of sea-
weeds, in the prevention of PC [30]. Seaweeds rich in
polyphenols [31] have been shown to exert antitumor [32]
potential, particularly in inhibiting cancer cell proliferation
[33], tumor regression [34], and metastasis [35]. Recently,
we have defined the anti-PC potential of polarity-based
polyphenol extractions from five different seaweeds and
further recognized the potential molecular targets in this
setting [36]. Screening 20 polyphenol fractions in terms of
their anti-oxidant capacity, and ability to inhibit cell viabil-
ity, cell survival, DNA fragmentation, apoptosis, functional
activation of NFκB, transcription/translation of key (Bcl2,
PDGFA, AKT, kRAS, EGFR, VEGF, TERT, FGF) onco-
genes and tumor progression molecules in genetically di-
verse PC cells identified three polyphenols (ethyl acetate
fractions of Hormophysa triquerta HT, Spatoglossum
asperum SA, Padina tetrastromatica PT) with superior
anti-tumor activity. Accordingly, in this study, we used a
clinically translatable residual PC model to investigate the
clinical benefits of seaweed polyphenols in regulating the
onset and maintenance of autophagy, particularly in the
cells that survive first-line therapy. Achieving such ben-
efits from the polarity gradient polyphenol fractions of
seaweeds might identify potential adjuvant(s) that could
be an effective modulator of autophagy in residual PC.
Methods
Cell culture
Genetically diverse human Panc-3.27 (ATCC-CRL2549)
and MiaPaCa-2 (ATCC-1420) cells were obtained from Dr.
Daniel J. Brackett (Department of surgery, University of
Oklahoma Health Sciences Center, Oklahoma City, OK).
Culture and maintenance of Panc-3.27 and MiaPaCa-2
cells were performed as described earlier [36,37]. For
passage and for all experiments, the cells were detached
using trypsin (0.25%)/EDTA (1%) resuspended in complete
medium, counted electronically using a Countess auto-
mated cell counter (Carlsbad, CA, USA), and incubated in
a 95% air/5% CO2 humidified incubator.
Xenotransplantation mouse model
All experiments conformed to American Physiological
Society standards for Animal Care and were carried out
in accordance with the guidelines laid down by the Na-
tional Research Council. Protocols were approved by our
Institutional Animal Care and Use Committee before
work began. Seven-week-old male athymic NCr-nu/nu
nude mice (NCI, Frederick, MD) weighing 25-30 g were
acclimatized for at least 3 days before the study. The
mice were anesthetized using 0.2 ml of ketamine
(10 mg/ml) and xylazine (1 mg/ml) in sterile phosphate
buffered saline (PBS) via intraperitoneal injection, before
the tumor xenograft and irradiation procedures. We
subcutaneously administered 5×106 human Panc-3.27 or
MiaPaCa-2cells suspended in 30% Matrigel (BD Biosci-
ences) into the animals’ right flanks. Tumor growth was
periodically monitored. Tumors were allowed to grow to
a volume of up to 100 mm3. Six animals were used per
treatment group, and animals were randomly allocated
to each group [38-42]. Animals were monitored and
checked by veterinary staff daily, and weighed twice a
week. All efforts were made to minimize and alleviate
animal discomfort. An animal was considered to be in
distress if it experienced any of the following: loss of
25% or more body weight, unthriftiness (inability to
walk, run, eat or drink properly) due to injury or poten-
tial tumor load, became moribund and lethargic, or de-
veloped visible and/or necrotic tumors. Mice that
displayed bleeding, wounds, any other symptoms that
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affected posture, or appeared to be uncomfortable were
sacrificed early. At the end of each experiment, animals
were euthanized by CO2 asphyxiation. Xenografts were
harvested and subjected to downstream endpoint analysis.
In vitro and In vivo irradiation procedures
In the radiation experiments, Panc-3.27 or MiaPaCa-2
cells were either mock-irradiated or exposed to FIR (2
Gray (Gy)/day for 5 days) using a Gamma Cell 40
Exactor (Nordion International Inc., Ontario, Canada) at
a dose rate of 0.81 Gy/min. In vivo PC xenografts estab-
lished from corresponding PC cells were selectively ex-
posed to clinically relevant FIR (2 Gy/day for 5 days/
week for a total of 3 weeks) to a total dose of 30 Gy. A
specially designed cerrobend shield was used to encase
the body of the mice, exposing only the flank tumors, as
described earlier [43-45]. Mock-irradiated animals were
treated identically, except that they were not subjected
to radiation. For all in vivo experiments we used a tumor
(xenograft) focused clinically relevant fractionated radi-
ation dose regimen (2Gy/Day for 5 days/week for three
weeks with a total dose of 30Gy). In each case, FIR alone
group or with the seaweed polyphenol treatments, we
started radiotherapy as early as the tumor reaches
100 mm3. This approach particularly allowed us to es-
tablish a clinically relevant residual tumor model, avoid-
ing any bulk tumor with the possibility of tumor mass/
cells that spared out of radio-therapeutic field. At the
end of complete radiation dose regimen with or without
seaweed polyphenol(s) treatment, the tumor xenografts
were maximally reduced, residual and beyond any un-
biased comparable measure between groups. Hence,
tumor growth measurements in response to radiother-
apy as well as with the seaweed polyphenols are not in-
cluded in this study.
Polarity gradient polyphenol(s) extraction and cell
treatments
Cells were plated in 100 mm tissue culture plates con-
taining 6 ml of complete growth medium and were
allowed to grow up to 80% confluence. Polarity-based
extractions of seaweed polyphenol fractions were per-
formed as described earlier [36]. We selectively exam-
ined ethyl acetate fractions of Hormophysa triquerta
(HT), Spatoglossum asperum (SA), and Padina tetrastro-
matica (PT) those demonstrated superior anti-PC activ-
ity measured in terms of their ability to inhibit cell
viability, cell survival, DNA fragmentation, apoptosis,
functional activation of NFκB, transcription/translation
of key (Bcl2, PDGFA, AKT, kRAS, EGFR, VEGF, TERT,
FGF) oncogenes and tumor progression markers [36]. For
all in vitro investigations, cells were treated with 100 μg/
ml of each polyphenol fraction, while corresponding
10 mg/Kg concentration was used for in vivo studies.
Quantitative Real-time PCR
Total RNA extraction and individual gene transcriptional
levels were investigated as described earlier [46,47]. Tran-
scriptional alterations of ATG3, ATG5, ATG7, ATG12,
TLR-1, TLR-2, TLR-3, TLR-4, TLR-5, TLR-6, TLR-7, TLR-
8, TLR-9, HMGB-1, RAGE, LC3A, LC3B, Beclin, and
MYD88 were investigated. For this, we adopted two ap-
proaches: (i) PC cells pre-treated with select seaweed
polyphenol were then exposed to fractionated irradi-
ation and, (ii) cells exposed to fractionated irradiation
were treated with seaweed polyphenol. We used β-actin
as a positive control. A negative control without tem-
plate RNA was also included. Each experiment was car-
ried out in triplicate. The ΔΔCt values were calculated
by normalizing the gene expression levels to β-actin. The
relative expression level was expressed as fold change.
Group-wise comparisons were made using ANOVA with
Tukey’s post-hoc correction. A P value of <0.05 was con-
sidered statistically significant.
Bromodeoxyuridine (BrdU)-incorporation cell proliferation
assay
Serum starved MiaPaCa-2 or Panc-3.27 cells that were
either mock-irradiated, exposed to fractionated irradi-
ation (2Gyx5), treated with SA-EA, PT-EA or SA-EA,
treated with SA-EA, PT-EA or SA-EA and exposed to
FIR, exposed to FIR and treated with SA-EA, PT-EA or
SA-EA or LC3B silenced and exposed to mock-IR or FIR
were transferred to 96-well plates (2x103/well). Twenty-
four hours after stimulation with FBS, cells were treated
with BrdU (1 μM) for 2 h, washed and fixed in sucrose
supplemented 3% paraformaldehyde in PBS. Fixed cells
were serially treated with 0.1% triton buffer and 2 M HCl
with excessive intermittent PBS washing. The cells were
then blocked (0.1% BSA in PBS), tagged with anti-BrdU
mouse antibody (for 1 h at 37°C), washed and second
labelled with goat-anti mouse Alex Flour-488. Unlabeled
nucleus were then stained with DAPI and analyzed in Op-
eretta high content confocal imaging. BrdU incorporation
was captured for 63 different fields/well with three differ-
ent Z planes. Quantification of the total and BrdU incor-
porated nuclei are counted using Operetta integrated
automated Columbus image analysis software. Group-wise
comparisons were computed using GraphPad PRISM and
analyzed using Two-way ANOVA with Tukey’s post-hoc
correction.
Plasmid preparation and DNA transfection
To define the role of autophagy signaling in the prolifer-
ation of PC cells that survive radiotherapy, we inhibited
LC3B, the well documented autophagic marker, the
amount of which correlates with the amount of autopha-
gic membranes and examined for the alterations in cell
proliferation. Transient transfection of LC3B shRNA
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(MISSION® shRNA, Sigma-Aldrich) in human MiaPaCa-
2 and Panc-3.27 cells were carried out by using either
TurboFectin 8.0 reagent (Origene) or Neon electropor-
ation transfection system (Life Technologies).
TMA construction and immunohistochemistry/
immunofluorescence
All TMA construction procedures and automated IHC
were performed in the Charles Stephenson Cancer Cen-
ter Cancer Tissue Pathology Core. Briefly, harvested PC
xenografts were fixed in 10% buffered formaldehyde,
embedded in paraffin, and used to extract individual tis-
sue cores. All H&E stained slides were reviewed for path-
ology. We selected the most representative areas of tumor
cells for tumor sampling. We examined TMA constructed
from residual PC xenografts after clinical doses of frac-
tionated radiotherapy for cellular localization and expres-
sion of survivin (Santa Cruz), LC3A, LC3B, ATG3,
ATG5, ATG12, and Beclin1 (Cell Signaling Technology
Inc., Danvers, MA, USA). Appropriate tissue morpho-
logic/pathologic (Hematoxylin and Eosin, H&E) con-
trols, positive expression controls, and negative (no
primary antibody (Ab) controls were examined in par-
allel. The slides were micro-digitally scanned using a
Scanscope (Aperio) slide scanner and analyzed using
integrated Spectrum software. For Beclin1 (Santa Cruz),
the primary protein was tagged with Alexa Fluor 488
(Abcam), while the cell membrane was marked with wheat
germ agglutinin (WGA) Alexa Fluor 594 (Invitrogen)
and nuclear counterstained with DAPI. Immunofluor-
escence was measured with the high-throughput optical
imager Operetta (Perkin Elmer) and analyzed with the
integrated Columbus image data storage and analysis
system (Perkin Elmer).
Results
Activated autophagy machinery in resistant PC cells after
first-line Radiotherapy
To better characterize the autophagy phenotype of the
PC cells that survive first-line therapy, we examined the
transcriptional modulation of autophagy functional regu-
lators ATG3, ATG5, ATG7, ATG12, TLR-1, TLR-2, TLR-3,
TLR-4, TLR-5, TLR-6, TLR-7, TLR-8, TLR-9, HMGB-1,
RAGE, LC3A, LC3B, Beclin, and MYD88, in genetically
diverse human Panc-3.27 and MiaPaCa-2 cells exposed
to clinically relevant fractionated radiation (2 Gy/Day for
5 days). Real-time QPCR revealed a significant (P < 0.001)
induction of ATG3, ATG5, ATG7, ATG12, HMGB-1,
RAGE, LC3A, LC3B, Beclin, MYD88 (Figure 1), TLR-1,
TLR-2, TLR-3, TLR-4, TLR-5, TLR-6, TLR-7, TLR-8, and
TLR-9 (Figure 2) in both cell lines after FIR. We ob-
served a robust activation of these molecules in Panc-3.27
cells compared with MiaPaCa-2 cells. Although the acti-
vated transcription was evident in MiaPaCa-2 cells, the
activation of ATG3, HMGB1, RAGE, TLR-1, TLR-2, TLR-3,
TLR-6 and TLR-9 were marginal after FIR. Therapy-
associated activation of these molecules, except TLR-2,
was profound (>10 fold) in Panc-3.27 cells. Activation of
these functional regulators of autophagy and its signal
transduction flow through demonstrates the intrinsic in-
fluence of the autophagy-associated survival response in
therapy-resistant PC cells.
Seaweed polyphenols target therapy-orchestrated
autophagy transcriptional machinery in surviving PC cells
To determine the potential of seaweed polyphenols in
targeting radiotherapy-induced regulation of autophagy
in surviving PC cells, we examined the transcriptional
modulation of ATG3, ATG5, ATG7, ATG12, TLR-1, TLR-
2, TLR-3, TLR-4, TLR-5, TLR-6, TLR-7, TLR-8, TLR-9,
HMGB-1, RAGE, LC3A, LC3B, Beclin, and MYD88 in
Panc-3.27 and MiaPaCa-2 cells. Cells were pretreated
with SA-EA, PT-EA, and HT-EA fractions and exposed
to radiotherapy (2 Gy x 5 days). Therapy-associated acti-
vation of ATG3 was significantly inhibited in both cells
lines in the presence of SA-EA, PT-EA, and HT-EA frac-
tions (Figure 1). All three fractions consistently induced
cell-line independent inhibition of FIR-induced ATG5
transcription in PC cells (Figure 1). PT-EA prompted
maximum inhibitory efficiency of ATG5 in MiaPaCa-2
cells, while HT-EA showed more efficiency in Panc-3.27
cells. Moreover, we observed significant inhibition of
therapy-associated ATG7 transactivation in both cell lines
with SA-EA, PT-EA, and HT-EA treatment (Figure 1).
Further, QPCR analysis recognized the definite inhibition
of radiotherapy-induced ATG12 transactivation in PC cells
in the presence of seaweed polyphenols (Figure 1), with
maximum efficiency of PT-EA in MiaPaCa-2 and HT-
EA in Panc-3.27 cells. Autophagic flux markers LC3A
and LC3B were significantly activated in response to ther-
apy, and were completely suppressed in PC cells treated
with SA-EA, PT-EA, or HT-EA fractions (Figure 1).
Though we observed marginal variations in LC3A and
LC3B inhibition between the polyphenol fractions, all
three polyphenols inflicted maximal (P < 0.001) tran-
scriptional repression of these two genes. These high
polarity-based extractions of seaweeds also demon-
strated a cell-line independent inhibition of autophagy
signaling genes, including HMGB1, RAGE and Myd88,
in radio-resistant PC cells (Figure 1). Similarly, all three
fractions imposed significant cell-line independent in-
hibition of FIR-induced Beclin (ATG6) transcription in
PC cells (P < 0.001, Figure 1). SA-EA induced max-
imum inhibitory efficiency in MiaPaCa-2 cells, while
PT-EA showed more efficiency in Panc-3.27 cells.
Since Toll-like receptors (TLRs) are intrinsically in-
volved in micro-autophagy and have been shown to be
activated in response to therapy in many tumor models,
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we investigated the potential of seaweed polyphenols in
the regulation of therapy-orchestrated TLR signaling in
macroautophagy. QPCR analysis revealed a marked de-
crease in the radiotherapy-induced TLRs-1, -2, -3,-4, -5, -6,
-7, -8, and -9 in MiaPaCa-2 and Panc-3.27 cells (Figure 2).
All fractions exhibited similar inhibitory profiles with mar-
ginal variations. Though there was no notable increase in
TLR-2 after therapy, the fractions defined the inhibition
of constitutive TLR2 in this setting. Taken together, the
results recognized the regulation potential of SA-EA,
PT-EA, and HT-EA fractions in the autophagy machin-
ery that drives the survival of PC cells after therapy.
Further, to determine the post-radiation (radio-protec-
tion) benefit of seaweed polyphenol in the regulation of
autophagy transcriptional machinery, if any, we exam-
ined the transcriptional modulation of ATG3, ATG5,
ATG7, ATG12, LC3A, LC3B and Beclin in MiaPaCa-2
cells. Cells exposed to FIR were then treated with SA-EA,
PT-EA, and HT-EA fractions. Radiation-induced activa-
tion of ATG3 was significantly inhibited in the presence of
SA-EA, PT-EA, and HT-EA fractions (Figure 3A). All
three fractions consistently inflicted inhibition of FIR-
induced ATG5 transcription (Figure 3A). Moreover, we
observed significant inhibition of radiation-associated
ATG7 transactivation with SA-EA, PT-EA, and HT-EA
treatment (Figure 3A). Further, QPCR analysis recognized
the definite inhibition of radiotherapy-induced ATG12
transactivation in PC cells in the presence of seaweed
polyphenols. Autophagic flux markers LC3A and LC3B
that were significantly activated in response to radiotherapy
were completely suppressed in MiaPaCa-2 cells treated
with SA-EA, PT-EA, or HT-EA fractions (Figure 3A).
Similarly, all three fractions imposed significant inhibition
of FIR-induced Beclin (ATG6) transcription (Figure 3A).
Together, these date demonstrate that treatment of
radio-resistant PC cells with seaweed polyphenols ex-
hibit significant inhibition of autophagy transcriptional
machinery implying the possible benefit of these frac-
tions in autophagy dependent radioprotection of sur-
viving PC cells.
Seaweed polyphenols exercise anti-tumor activity and
promotes radio-sensitization/radio-protection in PC cells
Number of studies has recognized the activation of prolif-
eration/clonal expansion capabilities in tumor cells that
survive after fractionated radiation [48,49]. Further, we
demonstrated the activation NFκB-dependent survival sig-
naling after fractionated irradiation in multifarious tumor
models [50,51] including pancreatic cancer [37]. To deter-
mine the benefit of the seaweed polyphenols in PC cell
radio-sensitization and/or radio-protection, we adopted
three approaches. First, MiaPaCa-2 cells treated with SA-
EA, PT-EA or HT-EA as stand-alone compounds were ex-
amined for their anti-tumor activity. Compared to the
mock-irradiated controls, BrdU incorporation assay re-
vealed a significant inhibition of PC cell proliferation with
SA-EA (P < 0.01), PT-EA (P < 0.05) and HT-EA (P < 0.001)
treatment (Figure 3B). Next, MiaPaCa-2 cell pre-treated
with seaweed polyphenols were exposed to FIR and exam-
ined for their radio-sensitization potential. Parallel FIR
exposed cells were used as controls. Compared to the
mock-irradiated cells, we observed a significant activation
of cell proliferation in cells that survive FIR. Conversely,
cells pretreated with SA-EA, PT-EA or HT-EA and ex-
posed to FIR revealed a complete (P < 0.001) suppression
of FIR-associated increase in cell proliferation (Figure 3B)
demonstrating the radio-sensitizing potential of all three
seaweed polyphenols investigated. Finally, MiaPaCa-2 cell
exposed to fractionated irradiation were then treated with
SA-EA, PT-EA or HT-EA and examined for their radio-
protection potential. Interestingly, treating the radio-
resistant cells with seaweed polyphenols significantly (P <
0.001) reduced the cell-proliferation capacity implying
their radio-protecting benefit in this setting (Figure 3B).
Together, these data corroborates well with the autoph-
agy transcriptional machinery alterations data and identify
the novel radio-sensitizing as well as radio-protecting po-
tential of seaweed polyphenols.
Autophagy mediates cell proliferation in radio-resistant
cells
Further to define the role of autophagy on activated cell
proliferation in PC cells that survive radiotherapy, LC3B
silenced MiaPaCa-2 and Panc-3.27 cells were exposed to
mock-IR or 2Gy radiation and analyzed for alterations in
cell proliferation. Compared to the mock-irradiated con-
trols, BrdU incorporation assay demonstrated a significant
decrease in cell proliferation in LC3B muted MiaPaCa-2
(P < 0.001) and Panc-3.27 (P < 0.05) cells (Figure 3C). Cells
that survive the radiation exposure exhibited robust (P <
0.001) proliferation rate. More importantly, the increased
proliferation in cells that survive radiation was significantly
attenuated in both MiaPaCa-2 and Panc-3.27 cells when
autophagy marker, LC3B was silenced (Figure 3C). To-
gether, these results demonstrate that onset of autophagy
(See figure on previous page.)
Figure 1 Individual gene QPCR analysis showing transcriptional modulations of ATG3, ATG5, ATG7, ATG12, LC3A, LC3B, Belcin1, MyD88, HMGB1, and
RAGE in Panc-3.27 and MiaPaCa-2 cells, either mock-irradiated, exposed to FIR (2Gy x 5d) or pretreated with 100 μg/ml of SA-EA, PT-EA, or HT-EA
seaweed polyphenol fractions and exposed to FIR. Pretreating the cells with seaweed polyphenols significantly attenuated radiotherapy-induced
ATG3, ATG5, ATG7, ATG12, LC3A, LC3B, Belcin1, MyD88, HMGB1, and RAGE transcription in Panc-3.27 and MiaPaCa-2 cells.
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Figure 2 (See legend on next page.)
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(See figure on previous page.)
Figure 2 Individual gene QPCR analysis showing transcriptional modulations of TLRs (TLR 1-9) in Panc-3.27 and MiaPaCa-2 cells, either mock-irradiated,
exposed to FIR (2Gy x 5d) or pretreated with 100 μg/ml of SA-EA, PT-EA, or HT-EA seaweed polyphenol fractions and exposed to FIR. Pretreating the
cells with seaweed polyphenols significantly attenuated radiotherapy-induced TLRs 1-9 in transcription in Panc-3.27 and MiaPaCa-2 cells.
Figure 3 (See legend on next page.)
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mediates activated cell proliferation in therapy resistant PC
cells.
SA-EA, PT-EA, and HT-EA fractions regulate ATG3, ATG5,
ATG12, survivin, LC3A, LC3B, and beclin expression and
localization in residual tumors in vivo
To further substantiate that ethyl acetate fraction of SA,
PT, and HT polyphenols regulate crucial and defined
autophagic players that functionally orchestrate PC sur-
vival after first-line therapy, we examined the cellular ex-
pression levels of ATG3, ATG5, ATG12, survivin, LC3A,
LC3B, and beclin in residual human PC tumors. We se-
lectively exposed human PC xenografts established with
MiaPaCa-2 cells in athymic nude mice to FIR (2 Gy/day
for 5 days/week for three weeks) to a total dose of
30 Gy, with or without a daily dose of SA-EA, PT-EA,
or HT-EA. To avoid IHC staining inconsistencies across
samples, TMA was constructed with the xenografts and
the protein localizations were examined with automated
IHC coupled with micro digital scanning (Aperio) and
spectrum analysis. TMA cores were carefully constructed
utilizing histopathological evaluations of individual H&E
stained tumor tissues and further confirmed with TMA-
H&E staining. IHC staining analysis of autophagocytosis-
associated protein ATG3 revealed basal levels of positivity
in mock-irradiated xenografts. ATG3 positive staining ap-
peared in brown, and was predominantly localized in the
cytoplasm (Figure 4 pullout). Compared with mock-
irradiated controls, ATG3 immunoreactivity was intense
and present in 37.511 ± 5.69% of the PC cells in residual
tumors after clinical doses of FIR (Figure 5). Conversely,
we observed a complete loss of ATG3 immunoreactivity
(See figure on previous page.)
Figure 3 Seaweed polyphenols exerts autophagy dependent anti-tumor activity and promotes radio-sensitization/radio-protection in PC cells.
(A) Individual gene QPCR analysis showing transcriptional modulations of ATG3, ATG5, ATG7, ATG12, LC3A, LC3B and Belcin1 in MiaPaCa-2 cells,
either mock-irradiated, exposed to FIR (2Gy x 5d) or exposed to FIR and treated with 100 μg/ml of SA-EA, PT-EA, or HT-EA seaweed polyphenol fractions.
Treating the radio-resistant cells with seaweed polyphenols significantly inhibited ATG3, ATG5, ATG7, ATG12, LC3A, LC3B and Belcin1 transcription in
radio-resistant Panc-3.27 and MiaPaCa-2 cells. (B) Representative images of Operetta high-throughput confocal imaging showing BrdU incorporation
levels in MiaPaCa-2 cells either mock irradiated, exposed to fractionated irradiation (FIR, 2Gy x 5d), exposed to seaweed polyphenols (SA-EA, PT-EA or
HT-EA - 100 g/ml), exposed to each seaweed polyphenols followed by FIR or exposed to FIR followed by seaweed polyphenol treatment. Histograms
obtained from Operetta integrated automated Columbus image analysis software computed BrdU incorporation for 63 different fields/well showing
significant reduction in radiotherapy-induced proliferating cells with seaweed polyphenol treatment. (C) Representative images of Operetta
high-throughput confocal imaging showing BrdU incorporation levels in MiaPaCa-2 and Panc-3.27 cells either mock irradiated, exposed to radiation
(2Gy), LC3B silenced or LC3B silenced and exposed to IR. Histograms obtained from automated Columbus image analysis computed BrdU
incorporation (for 63 different fields/well) showing significant reduction in radiotherapy-activated cell proliferation with LC3B silencing.
Figure 4 Representative microphotographs from ATG3-stained PC tissue micro array (TMA) constructed with xenografts (established from MiaPaCa-2)
exposed to mock-irradiation or fractionated irradiation with or without SA-EA, PT-EA, and HT-EA fractions. Pullout shows the staining pattern
(20x magnification).
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in tumors from mice that received SA-EA and were ex-
posed to FIR. ATG3 immunoreactivity was completely re-
duced to basal (mock-IR) or lower levels in all residual
tumors from animals treated with PT-EA in conjunction
with radiotherapy (Figure 5B). Likewise, HT-EA treatment
in combination with radiotherapy produced a complete
inhibition of ATG3 cellular localization in residual PC
tumors. SA-EA exhibited profound ATG3 inhibition in re-
sidual PC tumors after first-line radiotherapy.
Figure 6 shows the representative results of IHC for
autophagocytosis-associated protein ATG5 in PC xeno-
grafts that were either mock-irradiated or exposed to
clinical FIR, with or without SA-EA, PT-EA, or HT-EA
treatment. There was no detectable immunoreactivity
with the negative control (data not shown). ATG5 ex-
pression was stronger in tumor cells than in stromal
cells (Figure 6 pullout). Though ATG5 was detectable in
all analyzed xenografts, radiotherapy-treated xenografts
showed strong ATG5 expression. There was a significant
difference of ATG5 expression between FIR-only and
FIR with seaweed polyphenol(s) groups (Figure 5B). SA-
EA and PT-EA treatments showed low levels of ATG5,
compared with the FIR group. ATG5 expression was
barely detectable with HT-EA treatment. All selected
specimens of PC xenograft tissues contained ATG12–
positive cells. Stained cytoplasm appeared dark brown in
color and was mainly present in epithelial cells (Figure 7
pullout). ATG12 positivity ranged from 4.84 ± 2.65% of
mock-irradiated xenografts to 54.098 ± 8.08% of irradiated
residual tumors (Figure 5B). The range for ATG12–
positive epithelial cells was <10% in animals that received
SA-EA in conjunction with radiotherapy. However, the
mean fraction of ATG12–positive nuclei was 48.668 ±
3.23% in xenografts of animals that received radiotherapy
and PT-EA. HT-EA treatment yielded about 17.718 ±
6.09% ATG12–positive epithelial cells (Figure 5B).
IHC staining of survivin revealed basal levels of posi-
tivity in mock-irradiated xenografts. The positive stain-
ing of survivin appeared in dark brown, and was
localized in both the cytoplasm and the nucleus (Figure 8
pullout). There was no staining observed with the nega-
tive control for survivin (data not shown). Compared
with the mock-irradiated controls, survivin immunoreac-
tivity was intense and present in 70.998 + 1.621% of the
PC cells in residual tumors after clinical doses of FIR
(Figure 5). However, we observed a significant (P <
0.001) reduction in survivin immunoreactivity in tumors
of mice that received SA-EA or HT-EA and were ex-
posed to FIR. Figure 9 shows representative results of
IHC for microtubule-associated protein 1 light chain 3
Figure 5 Seaweed polyphenol treatments regulate autophagy related (ATG3, ATG5, ATG12, LC3A, LC3B, Survivin ) protein expression in radiotherapy
resistant residual PC tumors. (A) Images of TMAs labelled (automated IHC) for Blank (no primary antibody), hematoxylin-eosin, ATG3, ATG5, ATG12,
LC3A, LC3B, and survivin. (B) Aperio TMA-quantitation analysis showing protein specific positivity magnitudes in mock-irradiated PC xenografts and
residual PC tissues after clinical radiotherapy with or without SA-EA, PT-EA, or HT-EA treatment. Group-wise comparisons were made using Two-way
ANOVA with Bonferroni’s post-hoc correction.
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(LC3A) in PC xenografts that were either mock-irradiated
or exposed to clinical FIR, with or without SA-EA, PT-EA,
or HT-EA. We observed no detectable immunoreactivity
of LC3A in the mock-irradiated group. In xenografts
exposed to clinical radiotherapy, we observed a strong de-
tectable LC3A immunoreactivity that was predominantly
localized in the cytoplasm (Figure 9 pullout). PC xenografts
from animals that received radiotherapy in conjunction
with SA-EA showed little to no detectable cytoplasmic
LC3A. Similarly, we did not see any detectable LC3A im-
munoreactivity in tumors of animals that received radio-
therapy in combination with PT-EA or HT-EA (Figure 5B).
Figure 6 Representative microphotographs from ATG5-stained PC TMA constructed with xenografts (established from MiaPaCa-2) exposed to
mock-irradiation or fractionated irradiation, with or without SA-EA, PT-EA, and HT-EA fractions. Pullout shows the staining pattern (20x magnification).
Figure 7 Representative microphotographs from ATG12-stained PC TMA constructed with xenografts (established from MiaPaCa-2) exposed to
mock-irradiation or fractionated irradiation, with or without SA-EA, PT-EA, and HT-EA fractions. Pullout shows the staining pattern (20x magnification).
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We examined cellular localization levels of microtubule-
associated protein 1 light chain 3B (LC3B) in human PC
xenografts after radiotherapy in conjunction with SA-EA,
PT-EA, or HT-EA treatment (Figure 10). LC3B immuno-
reactivity was detectable in mock-irradiated human PC
xenografts, consistent with the comparable levels re-
ported in human PC (www.proteinatlas.org). However,
the tumors surviving after clinical radiotherapy exhibited
high immunoreactivity for LC3B localization (70.663 ±
0.998%). LC3B positive staining appeared in brown, and
Figure 8 Representative microphotographs from survivin-stained PC TMA constructed with xenografts (established from MiaPaCa-2) exposed to
mock-irradiation or fractionated irradiation, with or without SA-EA, PT-EA, and HT-EA fractions. Pullout shows the staining pattern (20x magnification).
Figure 9 Representative microphotographs from LC3A-stained PC TMA constructed with xenografts (established from MiaPaCa-2) exposed to
mock-irradiation or fractionated irradiation, with or without SA-EA, PT-EA, and HT-EA fractions. Pullout shows the staining pattern (20x magnification).
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was predominantly localized in the cytoplasm in a punctu-
ated pattern (Figure 10 pullout). Regulation of the
radiotherapy-induced localization of LC3B was evident in
PC tissues from animals that received SA-EA, PT-EA, and
HT-EA treatment (Figure 5). HT-EA treatment showed the
high regulatory potential of radiotherapy-associated LC3B
localization. We also examined beclin-1, a mammalian
ortholog of the yeast autophagy-related gene 6 (BECN1)
protein that has been shown to have relatively high levels
of localization in PC tissues (www.proteinatlas.org), in hu-
man PC xenografts after radiotherapy, with or without
treatment with seaweed polyphenol fractions (Figure 11).
Figure 10 Representative microphotographs from LC3B-stained PC TMA constructed with xenografts (established from MiaPaCa-2) exposed to
mock-irradiation or fractionated irradiation, with or without SA-EA, PT-EA, and HT-EA fractions. Pullout shows the staining pattern (20x magnification).
Figure 11 Representative microphotographs from Beclin1-stained PC TMA constructed with xenografts (established from MiaPaCa-2) exposed to
mock-irradiation or fractionated irradiation, with or without SA-EA, PT-EA, and HT-EA fractions. Pullout shows the staining pattern (20x magnification).
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Mock-irradiated PC tumors showed detectable BECN1 im-
munoreactivity. Immunofluorescence was highly intense
and present in 49.982 ± 3.284% of the PC cells in residual
tumors after clinical FIR (Figure 5B). BECN1 positive
staining appeared in green (Alexa Fluor 488), and was
predominantly localized in cytoplasm (Figure 11 pullout).
Interestingly, radiotherapy combined with SA-EA, PT-EA,
or HT-EA completely regulated BECN1 localization in
residual PC tumors, compared with those tumors re-
ceiving radiotherapy alone. HT-EA treatment in con-
junction with radiotherapy significantly attenuated the
FIR-induced cellular localization of BECN1 in this setting.
Together, these data clearly portray the clinical benefit of
SA-EA, PT-EA, and HT-EA fractions in the regulation of
radiotherapy-orchestrated cellular localization of PC pro-
gression, driving survivin, ATG3, ATG5, ATG12, LC3A,
LC3B, and beclin in residual PC tumors.
Discussion
The role of the autophagic process in antitumor therapy
has not been clearly established [52,53]. After treatment
with antitumor drugs and/or radiation, some cancer cells
undergo autophagy as a temporary survival mechanism.
The suppression of autophagy leads to apoptosis, thus
enhancing antitumor effects. There are three primary
treatments for patients with exocrine PC: surgery, radi-
ation therapy, and chemotherapy. Autophagy can be ac-
tivated by chemotherapy and ionizing radiation in the
treatment of PC cells [20-23]. The cytoprotective role of
autophagy following chemotherapy and radiation ther-
apy has been confirmed by many investigators [25]. In
the present study using PC cells, we found that seaweed
polyphenols targeted autophagy that was activated in
response to first-line radiotherapy. Gemcitabine, as first-
line therapy for patients with advanced PC, triggers au-
tophagy in PC cells. Suppression of autophagy has been
shown to promote apoptotic cell death in response to
gemcitabine in PC [25,24]. Likewise, studies have shown
that zymophagy, mediated by the VMP1-USP9x-p62
pathway, prevents PC cell death [54]. Consistently, the
results of the present study revealed that muting autoph-
agy marker LC3B resulted in significant decrease in the
proliferation of cells that survive radiotherapy, implying
the decisive role of autophagy in the activated cell sur-
vival of therapy-resistant PC cells.
Gemcitabine treatment complemented with cannabi-
noids induces ROS-mediated autophagic cell death in
PC cells [55]. Radiation therapy and some forms of
chemotherapy rely on ROS toxicity to eradicate tumor
cells. Inhibition of autophagy or mitophagy increases
ROS production, resulting in apoptotic cell death. To
our knowledge, the present study is the first of its kind
to recognize the potential of seaweed polyphenol frac-
tions in the regulation of therapy-induced autophagy.
Utilizing in vitro and clinically mimicking in vivo re-
sidual tumor models, the present study identified the
autophagy-related molecular modulation that occurs
after first-line radiotherapy, and further defined the clin-
ical efficacy of high-polarity seaweed polyphenol frac-
tions with demonstrated anti-PC potential. High basal
autophagy in PC [18] is correlated with poor patient out-
comes [19]. Intensified LC3 expression in PC tissue is
associated with enhanced expression of carbonic anhy-
drase IX. More importantly, studies have shown that LC3
expression gradation is directly proportional to disease
progression, in which absent→ low→ high→ vesicular
LC3 staining corresponds to low-grade PanIN-1→
PanIN-2 lesions→ high-grade PanIN-3→ PDAC. Further,
these studies suggested that autophagy contributes to PC
progression. With this information, we investigated the ex-
pression levels of LC3A and LC3B in residual tumors after
radiotherapy. Our findings clearly showed increased tran-
scription of LC3A and LC3B in vitro, corresponding high
levels of LC3A and LC3B in residual tumors in vivo and,
demonstrate that muting LC3B significantly reduces cell
proliferation in therapy resistant cells. New to science, this
study demonstrate the LC3A and LC3B transcription and
translation inhibitory potential of seaweed polyphenol
fractions in surviving PC cells.
Conversely, studies have demonstrated that muting
autophagy genes, including ATG5 and ATG3, signifi-
cantly inhibits PC cell growth and colony formation of
PDAC cell lines in vitro [16]. The results of the present
study precisely delineated the benefits of SA-EA, PT-EA,
and HT-EA seaweed polyphenol fractions in targeting
radiotherapy-orchestrated LC3A and LC3B, and ATG3,
ATG5, and ATG12 in this setting. Comprehensive inhib-
ition of radiotherapy-orchestrated autophagy signaling by
these polyphenols could identify unique drug-deliverables
that could potentially impact PC treatment and yield better
patient outcomes. HMGB1, a highly conserved protein
containing HMG-box domains, regulates DNA replication,
repair, recombination, and gene transcription. During
stress, HMGB1 is released to the extracellular environment
and functions as a DAMP [56]. The major receptors for
HMGB1 are RAGE and TLR. Overexpression of HMGB1
and RAGE have been demonstrated in many tumors, in-
cluding PC [57,58]. RAGE is a member of the IgG super-
family and plays important roles in the regulation of ROS
generation and inflammatory response [59,60]. In PC,
RAGE is compatible with PanIn formation [61]. Gemcita-
bine promotes RAGE expression by ROS-mediated NFκB
activation [24]. This RAGE upregulation protects PC cells
against oxidative injury and increases drug resistance by in-
creasing autophagy and decreasing apoptosis [25].
The results of the present study showed increased
transcriptional activation of HMGB1, RAGE, and the
TLRs (TLRs1-9). As discussed above, though studies
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have demonstrated the activation of these molecules in
PC, to our knowledge this is the first observation of ele-
vated activation of these key molecules in PC cells that
survive therapy. Studies have shown that silencing
RAGE inhibits gemcitabine-, oxaliplatin-, or melphalan-
induced autophagy by regulating Beclin 1-Vps34 inter-
action [25]. Consistently, our observations revealed a
significant inhibition of HMGB1, RAGE, BECN1, and all
TLRs in PC cells following treatment with seaweed poly-
phenol(s). As RAGE and TLRs are required for extracel-
lular HMGB1-mediated autophagy [62], the cytosolic
HMGB1 directly interacts with Beclin 1, which is con-
trolled by the ULK1 complex [63,64]. Considering the
comprehensive inhibition of these crucial players with
the administration of seaweed polyphenols, we presume
that this signal transduction flow through is involved in
the polyphenol-associated inhibition of radiotherapy-
induced autophagy.
Studies have also shown that autophagy functions as
an anti-oncogenic mechanism in tumors [65-68]. It is
believed that autophagy partly promotes cancer develop-
ment through its ability to shape inflammatory reactions
[9], metabolic requirements [10], and oxidative stress
[11]. Thus, autophagy may play opposite roles in early
and late stages of cancer development. One possible ex-
planation for this difference is that the components of
metabolic stress, the immune response, and the micro-
environment are different. The inter-relationship between
autophagy and apoptosis might decide tumor cells’ fate. In
many cases, blockage of autophagy sensitizes tumor cells
to anticancer therapy, including chemotherapy, radiation,
and immunotherapy [69]. However, under certain condi-
tions like apoptosis deficiency, autophagy can also be pro-
death; this concept is termed “autophagic cell death”
[70,71]. The notion of autophagic cell death was first
established based on observations of increased autoph-
agic markers in dying cells. An increasing number of
studies indicate that autophagic cell death is cell death
with autophagy, rather than cell death by means of au-
tophagy [71,72].
The efficacy of autophagy inhibitors, including chloro-
quine or its derivatives, used in combination with che-
motherapeutic drugs, radiation, and immunotherapy has
been shown to inhibit acidification of the lysosome in
preclinical models. This combination therefore prevents
autophagy by blocking autophagosome fusion and deg-
radation. Current ongoing clinical trials examining the
benefit of autophagy inhibitors combined with gemcita-
bine in the treatment of PC are underway. These prelim-
inary studies suggest that autophagy can contribute to
PC progression. There is an immediate unmet need for
deliverables that could target this signaling and response.
The results of the present study identified three potential
seaweed fractions that could serve as drug-deliverables
against PC, particularly in the regulation of therapy-
associated autophagy, and could prompt a significant
archetypal shift in the treatment of PC patients.
Conclusions
Taken together, in vitro (genetically diverse human Panc-
3.27 and MiaPaCa-2 cells) and in vivo (clinically translat-
able residual PC mouse model) approaches coupled with
clinically relevant fractionated radiation dose regimens,
recognize the activation of autophagy signaling in radio-
therapy resistant pancreatic cancer cells and the influence
of autophagy on induced proliferation in surviving cells. In
addition, well characterized (proven anti-tumorigenic)
ethyl acetate polyphenol fractions from marine brown-
algae, Spatoglossum asperum (SA-EA), Padina tetra-
stromatica (PT-EA), or Harmophysa triquerta (HT-EA)
exerted anti-proliferation in therapy resistant PC cells.
Further, the results presented in this study demonstrate
that seaweed polyphenols prevent, as well as, target
radiotherapy-activated autophagy signaling and associated
radio-resistant cell proliferation. These data define the au-
tophagy blueprint in therapy-resistant PC cells and further
identify these polyphenols as adjuvants for potentiating
current PC treatment modalities, radiotherapy here in this
case, by targeting therapy orchestrated autophagy in re-
sidual cells. Further careful characterization of the com-
pounds, their pharmacokinetic profiling, cytotoxicity
profiling, in vivo bioavailability, and drug clearance evi-
dence coupled with tumor-targeted delivery approaches
would improve the outcomes of PC patients and, ultim-
ately, could save innumerable lives.
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